News coverage about Fresenius Medical Care Corporation (NYSE:FMS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fresenius Medical Care Corporation earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2567796850562 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Fresenius Medical Care Corporation (FMS) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business (finance.yahoo.com)
- Fresenius Medical Care Is a Global Leader in the Dialysis Segment (finance.yahoo.com)
- North America: Fresenius Medical Care’s Major Target Market in 2017 (marketrealist.com)
- Short Interest in Fresenius Medical Care Corporation (FMS) Declines By 42.0% (americanbankingnews.com)
Fresenius Medical Care Corporation (NYSE FMS) traded down 0.19% during mid-day trading on Friday, hitting $46.38. 101,389 shares of the stock traded hands. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22. The company has a 50-day moving average of $47.31 and a 200 day moving average of $44.97. The firm has a market capitalization of $28.46 billion, a P/E ratio of 20.34 and a beta of 0.47.
Fresenius Medical Care Corporation (NYSE:FMS) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by $0.05. The firm had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.96 earnings per share. On average, equities research analysts anticipate that Fresenius Medical Care Corporation will post $2.33 EPS for the current year.
A number of equities analysts recently commented on the stock. UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Royal Bank Of Canada restated a “neutral” rating and issued a price target on shares of Fresenius Medical Care Corporation in a research note on Tuesday, August 8th. DZ Bank AG restated a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, August 7th. Zacks Investment Research downgraded shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, BidaskClub downgraded shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $48.67.
COPYRIGHT VIOLATION NOTICE: This report was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/20/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-fresenius-medical-care-corporation-fms-stock-price-updated-updated-updated.html.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.